Crescendo Bioscience Lands $56M
South San Francisco-based Crescendo Bioscience, which develops molecular diagnostic tests for rheumatoid arthritis and other inflammatory diseases, said today that it has raised $31M in a Series C equity funding, plus a $25M strategic investment from Myriad Genetics. The Series C round was led by Aeris Capital AG, and also included Mohr Davidow Ventures, Kleiner Perkins Caufield & Byers and other investors. Crescendo Biosciences is led by William A. Hagstrom. The firm said the funding will go towards commercializing its Vectra DA product. Myriad Genetics gets a there year option to acquire Crescendo Bioscience for cash, based on a multiple of revenue and growth.
posted on Friday, September 9, 2011 (Link to more information)
Related companies:
Crescendo (Luxembourg) S.a r.l.
Related stories:
> Twist Bioscience Buys Genome Compiler
> Crystal Bioscience Acquired By Ligand For Up To $30.5M
> Twist Bioscience Gets $37M
> Twist Bioscience Adds $27M
> Crescendo Networks Adds $9.5M
silicontap.com Home